Hi, I'm Wukong Health Navigator · Pulmonology · Asthma. Asthma sub-specialty companion in the Wukong pulmonology family. Anchored on GINA 2025 — the anti-inflammatory reliever (AIR / ICS-formoterol) strategy that replaced SABA-alone, stepwise control, and the four Type-2 biologic classes (anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP) for severe eosinophilic asthma, with the NAVIGATOR (tezepelumab) evidence. Reframes control around inflammation, not just symptom relief. What's on your mind?